A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Inclusion Criteria:

1. Written informed consent is provided by patient or legally acceptablerepresentative;

2. Age ≥ 18 years;

3. Patient populations:

4. In the Safety Run-in, patients with histologically or cytologically confirmedadvanced or metastatic solid tumors who have disease progression aftertreatment with standard therapies for metastatic disease that are known toconfer clinical benefit, or are intolerant to treatment or refuse standardtreatment will be enrolled in therapy

5. In Expansion Phase, patient must have urothelial or NSCLC, and have failedprior anti-PD-1 or anti-PD-L1

6. Have measurable disease per RECIST 1.1 as assessed by the local siteinvestigator/radiology

7. Eastern Cooperative Oncology Group performance status of 0 to 1

8. Life expectancy of ≥ 3 months

Exclusion Criteria:

1. Positive urine pregnancy test within 72 hours prior to treatment

2. Has received prior systemic anti-cancer therapy including investigational agentswithin 4 weeks (or 5 half-lives, whichever is shorter) prior to treatment;

3. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent orwith an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), AND was discontinued from that treatment due to aGrade 3 or higher immune-related adverse event;

4. Has received prior radiotherapy within 2 weeks of start of study treatment.

5. For patients with NSCLC:

6. Patients who have received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of trial treatment are excluded;

7. Patients with mutations (e.g., EGFR mutations or ALK gene rearrangements) willbe excluded unless they have been previously treated with all specific targetedtherapies.

8. Has received a live or live-attenuated vaccine within 30 days prior to the firstdose of study intervention.

9. Has had an allogeneic tissue /solid organ transplant.